About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« 24th Annual Intellectual Property Law Conference | Main | Conference & CLE Calendar »

February 13, 2009

Biotech/Pharma Business Briefs

    By Jason Derry --

Merck to Buy Biologics Division from Insmed

Merck Insmed Inc. and Merck have announced a deal in which Merck will purchase Insmed's research and production division and facility for developing follow-on biologics for $130 million (see Insmed press release).  Merck will receive Insmed's follow-on biologics platform, and its development and production facility located in Boulder, CO.  Insmed's pipeline of follow-on biologics includes biosimilar versions of Amgen's Neupogen and Neulasta.  Merck is obtaining development and commercial rights for these follow-on biologic candidates.

Insmed #1


GSK Licenses HIV Drug Candidate

GlaxoSmithKline - GSK GlaxoSmithKline and Idenix Pharmaceuticals, Inc. have announced that GSK has licensed worldwide rights to Idenix's non-nucleoside reverse transcriptase inhibitor, IDX899, for treating HIV/AIDS (see Idenix press release).  The compound is currently in Phase II clinical development.  GSK will be responsible for continuing development.  Idenix will receive $34 million upfront, and may receive additional milestone payments of up to $416 million plus royalties.

Idenix Pharmaceuticals Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.

Posted at 11:43 PM in Biotech/Pharma Business |

Comments

The comments to this entry are closed.

September 2024

Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

Categories

Archives

More...